Diverse Biotech takes big step toward a new class of oncology drug candidates with its proprietary CuSP-C2 conjugate synthesis platform

Read Full Article At The Original Source

DOYLESTOWN, Pa., Dec. 10, 2019 /PRNewswire/ — Diverse Biotech, Inc. www.diversebiotech.com has announced it has successfully synthesized and progressed into pre-clinical testing its first two new chemical entities (NCEs) developed using its proprietary CuSP-C2 technology platform….


Author: HEDGE

Hedge Accordingly was founded ahead of the global financial crisis in January of 2008, with the goal of providing our readers our unique take on The Latest News on Wall Street, Stocks, #Politics and Business news. Hedge Accordingly produces both original, and aggregated #Wallst news content from top publishers around the world. We curate aggregated content covering the latest news on politics, stocks, wall street, and the tech industry. We also provide free stock charting, quotes and a bitcoin, forex and currency exchange. Learn More About HEDGEaccordingly.com